Inder Kaul

A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Evaluate the Safety and Efficacy of Recombinant Human Soluble Thrombomodulin, ART-123, in Patients With Sepsis and Suspected Disseminated Intravascular Coagulation*

Jean‐Louis Vincent, M Ramesh, David Ernest et al. · Critical Care Medicine · 2013 · 315 citations

Trial of SAGE-217 in Patients with Major Depressive Disorder

Handan Gunduz-Bruce, Christopher Silber, Inder Kaul et al. · New England Journal of Medicine · 2019 · 224 citations · Full text

Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline–trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial

Inder Kaul, Sharon Sawchak, Christoph U. Correll et al. · The Lancet · 2023 · 192 citations

Flexible-dose Phase 3, Psychiatry, Psychotic Disorder +9

Efficacy and Safety of Xanomeline-Trospium Chloride in Schizophrenia

Inder Kaul, Sharon Sawchak, David P. Walling et al. · JAMA Psychiatry · 2024 · 132 citations · Full text

SAGE-217, A Novel GABAA Receptor Positive Allosteric Modulator: Clinical Pharmacology and Tolerability in Randomized Phase I Dose-Finding Studies

Ethan Hoffmann, George G. Nomikos, Inder Kaul et al. · Clinical Pharmacokinetics · 2019 · 58 citations · Full text